Blass, Eryn Ott, Patrick A.
Published in
Nature Reviews. Clinical Oncology
Personalized therapeutic cancer vaccines predicated on neoantigens have been shown to be feasible, safe and immunogenic in patients with melanoma and glioblastoma. Different vaccine formats and delivery strategies are currently being tested in clinical studies involving patients with various tumour types. Deeper evaluation of the phenotypes, functi...
Poorebrahim, Mansour Melief, Jeroen Pico de Coaña, Yago L Wickström, Stina Cid-Arregui, Angel Kiessling, Rolf
Published in
Oncogene
In spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in vivo, conceivably induced by immunosuppressive tumor microenvironment (TME) and excessive antigen exposure. Exhaustion and senescence are two critical dysfuncti...
Gromeier, Matthias Brown, Michael C. Zhang, Gao Lin, Xiang Chen, Yeqing Wei, Zhi Beaubier, Nike Yan, Hai He, Yiping Desjardins, Annick
...
Published in
Nature Communications
Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.
Bunse, Mario Pfeilschifter, Janina Bluhm, Julia Zschummel, Maria Joedicke, Jara J. Wirges, Anthea Stark, Helen Kretschmer, Vivien Chmielewski, Markus Uckert, Wolfgang
...
Published in
Nature Communications
CAR-T cell therapy targeting CD19 is not as efficient to treat lymphoma with nodal dissemination as it is for B cell leukaemia. Here, the authors generate CAR-T cells against CXCR5 and show they inhibit tumour growth by depleting both B and follicular T helper cells in lymphoma models.
Wang, Bin Zhao, Qin Zhang, Yuyu Liu, Zijing Zheng, Zhuangzhuang Liu, Shiyu Meng, Lingbin Xin, Ying Jiang, Xin
Published in
Journal of Experimental & Clinical Cancer Research
With the success of immune checkpoint inhibitors (ICIs), significant progress has been made in the field of cancer immunotherapy. Despite the long-lasting outcomes in responders, the majority of patients with cancer still do not benefit from this revolutionary therapy. Increasing evidence suggests that one of the major barriers limiting the efficac...
Benmebarek, Mohamed-Reda Cadilha, Bruno L. Herrmann, Monika Lesch, Stefanie Schmitt, Saskia Stoiber, Stefan Darwich, Abbass Augsberger, Christian Brauchle, Bettina Rohrbacher, Lisa
...
Published in
Leukemia
Modular platform enabling controlled targeting of AML by SAR-transduced T cells in combination with tandem scFv constructs. Efficient lysis of primary AML blasts in vitro and strong antitumoral effects and T cell persistence in xenograft models.
Liu, Sizhe Galat, Vasiliy Galat4, Yekaterina Lee, Yoo Kyung Annie Wainwright, Derek Wu, Jennifer
Published in
Journal of Hematology & Oncology
Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively u...
Ye, Yilin Wang, Jian Xu, Yunwan Wang, Yi Pan, Youdong Song, Qi Liu, Xing Wan, Ji
Published in
BMC Bioinformatics
BackgroundAccurate prediction of binding between class I human leukocyte antigen (HLA) and neoepitope is critical for target identification within personalized T-cell based immunotherapy. Many recent prediction tools developed upon the deep learning algorithms and mass spectrometry data have indeed showed improvement on the average predicting power...
Ng, Wanyi Gong, Chenyuan Yan, Xuewei Si, Guifan Fang, Chen Wang, Lixin Zhu, Xiaowen Xu, Zihang Yao, Chao Zhu, Shiguo
...
Published in
Pharmaceutical Biology
Context Therapeutic benefits of immunotherapy are restricted by cancer immune-resistance mechanisms. Rediocide-A (Red-A), a natural product extracted from Traditional Chinese Medicine, is a promising agent to battle against cancer which acts as an immune checkpoint inhibitor. Objective To investigate the effect of Red-A on NK-cell tumouricidal acti...
Sahin, Dilara Arenas-Ramirez, Natalia Rath, Matthias Karakus, Ufuk Hümbelin, Monika van Gogh, Merel Borsig, Lubor Boyman, Onur
Published in
Nature Communications
IL-2/anti-IL-2 complexes have been proposed to curtail the severe adverse effects associated with IL-2 immunotherapy. Here, the authors, by integrating unmutated human IL-2 in the antigen binding groove of an anti-IL-2 monoclonal antibody, generate a CD122-biased fusion protein that prevents binding of IL-2 to CD25 and promotes anti-tumor immune re...